Department of Radiation Oncology

Results of Re-Chemoradiotherapy in Patients with relapsed Glioblastoma WHO IV (2019) Mansoorian S, Lettmaier S, Goerig N, Weissmann T, Semrau S, Fietkau R, Putz F Conference contribution Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy? (2019) Onbasi Y, Lettmaier S, Hecht M, Semrau S, Iro H, Kesting MR, Fietkau R, Haderlein M Journal article Impact of inter- and intra-observer variabilities of catheter reconstruction on multi-catheter interstitial brachytherapy of breast cancer patients (2019) Kallis K, Kaltsas T, Kreppner S, Lotter M, Strnad V, Fietkau R, Bert C Journal article Technical Note: A comparison of point set registration methods for electromagnetic tracking (2019) Götz TI, Wankerl H, Tomé AM, Meyer-Baese A, Bert C, Hensel B, Lang EW Journal article Beim HPV-assoziierten Oropharynxkarzinom ist die Radiochemotherapie mit Cisplatin der Bioradiotherapie mit Cetuximab in Bezug auf das Gesamtüberleben überlegen (2019) Semrau S Journal article Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - High locoregional control rates after photon (chemo) radiotherapy - Experience from a monocentric analysis (2019) Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Putz F, Iro H, et al. Journal article PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy (2019) Girard N, Mornex F, Christoph DC, Fietkau R, Filippi AR, Field J, Garrido Lopez P, et al. Conference contribution Chemo-RT plus induction or consolidation chemotherapy for rectal cancer: a randomised phase 2 trial (2019) Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution Radiotherapy with paclitaxel/cisplatin vs. fluorouracil/cisplatin for head and neck cancer (2019) Fietkau R, Hecht M, Hofner B, Iro H, Gefeller O, Roedel C, Hautmann M, et al. Conference contribution QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04) (2019) Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, et al. Conference contribution